Business Description
Neovacs SA
NAICS : 325412
SIC : 2834
ISIN : FR001400MV37
Compare
Compare
Traded in other countries / regions
ALNEV.France0LW0.Germany0W8U.UK IPO Date
2013-12-18Description
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.36 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.21 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -3.09 | |||||
| Beneish M-Score | -2469.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | 96.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.59 | |||||
| 9-Day RSI | 46.02 | |||||
| 14-Day RSI | 40 | |||||
| 6-1 Month Momentum % | -99.77 | |||||
| 12-1 Month Momentum % | -100 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | |||||
| Quick Ratio | 1.25 | |||||
| Cash Ratio | 0.29 | |||||
| Days Sales Outstanding | 161.08 | |||||
| Days Payable | 1621.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -12975 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 5.62 | |||||
| Operating Margin % | -2306.18 | |||||
| Net Margin % | -1637.27 | |||||
| FCF Margin % | -396.44 | |||||
| ROE % | -17.69 | |||||
| ROA % | -15.91 | |||||
| ROIC % | -23.21 | |||||
| ROC (Joel Greenblatt) % | -1928.06 | |||||
| ROCE % | -18.82 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 0.02 | |||||
| EV-to-EBITDA | 0.06 | |||||
| EV-to-Revenue | -0.36 | |||||
| EV-to-FCF | 0.09 | |||||
| Earnings Yield (Greenblatt) % | 5000 | |||||
| FCF Yield % | -4602.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neovacs SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.534 | ||
| EPS (TTM) (€) | -30825.983 | ||
| Beta | 0 | ||
| Volatility % | 965.21 | ||
| 14-Day RSI | 40 | ||
| 14-Day ATR (€) | 0.00246 | ||
| 20-Day SMA (€) | 0.001085 | ||
| 12-1 Month Momentum % | -100 | ||
| 52-Week Range (€) | 0.0001 - 400 | ||
| Shares Outstanding (Mil) | 28.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neovacs SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neovacs SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neovacs SA Frequently Asked Questions
What is Neovacs SA(STU:0LW0)'s stock price today?
The current price of STU:0LW0 is €0.00. The 52 week high of STU:0LW0 is €400.00 and 52 week low is €0.00.
When is next earnings date of Neovacs SA(STU:0LW0)?
The next earnings date of Neovacs SA(STU:0LW0) is .
Does Neovacs SA(STU:0LW0) pay dividends? If so, how much?
Neovacs SA(STU:0LW0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers